Cancer Gene Therapy
Research from S. Terao et al broadens understanding of cancer gene therapy
Published in Cancer Weekly, September 1st, 2009
According to recent research from Nishinomiya, Japan, "The effects on quality of life (QOL) after a Phase I/II clinical trial of a combination of osteocalcin promoter-driven herpes simplex virus thymidine kinase (Ad-OC-TK) gene therapy and valacyclovir (VAL) were investigated for patients with hormone-refractory prostate cancer (HRPC). The QOL of six patients was prospectively assessed after gene therapy on days 0, 14, and 28."
"A modified questionnaire was created based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire's prostate cancer-specific module (EORTC QLQ-PR25). The scores of all items significantly improved along...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-09-01)
More Articles from Cancer Weekly
- Acute Lymphoblastic Leukemia
Inherited Risk Factors Increase Odds of Developing Childhood Acute Lymphoblastic Leukemia - AntiCancer, Inc.
AntiCancer Inc. Develops New Gene-Based Fluorescence-Labeling Technology for Cancer Surgery - Biopharmaceuticals
Helix BioPharma Announces the Appointment of Kazimierz Roszkowski-Sliz, M.D., Ph.D., to its Board of Directors - Breast Cancer
Results In 'The New England Journal of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery - Cancer Gene Therapy
Reports outline cancer gene therapy study findings from National Cancer Institute - Cancer Gene Therapy
Research from B. Ying and co-authors reveals new findings on cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
